Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV1 | Q8NER1 | 5/20 | 0.57 |
| ▸ | NTRK1 | P04629 | 5/20 | 0.42 |
| ▸ | NTRK2 | Q16620 | 3/20 | 0.42 |
| ▸ | PDE10A | Q9Y233 | 3/20 | 0.40 |
| ▸ | RAB9A | P51151 | 3/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 2/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.35 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | QPCT | Q16769 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2241782 | 0.81 | TRPV1 (0.67) | TRPV1NTRK1NTRK2PDE10ARAB9A | |
| SCHEMBL2241285 | 0.80 | TRPV1 (0.85) | TRPV1NTRK1NTRK2PDE10ARAB9A | |
| SCHEMBL1794101 | 0.80 | TRPV1 (0.60) | TRPV1NTRK1NTRK2PDE10ARAB9A | |
| SCHEMBL2243168 | 0.78 | TRPV1 (0.60) | TRPV1NTRK1NTRK2 | |
| SCHEMBL2239628 | 0.78 | TRPV1 (0.85) | TRPV1NTRK1NTRK2PDE10ARAB9A | |
| SCHEMBL1797790 | 0.77 | TRPV1 (0.58) | TRPV1NTRK1NTRK2RAB9ANPC1 | |
| SCHEMBL2240498 | 0.77 | TRPV1 (0.67) | TRPV1NTRK1NTRK2RAB9ANPC1 | |
| SCHEMBL1797610 | 0.76 | TRPV1 (0.60) | TRPV1NTRK1NTRK2PDE10ARAB9A | |
| SCHEMBL12358874 | 0.76 | TRPV1 (0.45) | TRPV1NTRK1NTRK2PDE10ARAB9A | |
| SCHEMBL12359234 | 0.75 | RAB9A (0.53) | TRPV1PDE10ARAB9ANPC1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110190344-A1 | BENZIMIDAZOLE MODULATORS OF VR1 | JANSSEN PHARMACEUTICA N.V. (BE) | 2011-08-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110190344-A1 | BENZIMIDAZOLE MODULATORS OF VR1 | VRK1, VRK2, VIL1 | TRPV1 29/4885NTRK1 2537/4885NTRK2 2593/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.